micrometastatic disease

mi·cro·met·a·stat·ic dis·ease

the condition of a patient who has had all clinically evident cancer removed, but who may be expected to have a recurrence from metastases that are too small to be apparent.
References in periodicals archive ?
Therefore, it is important to treat micrometastatic disease with perioperative chemotherapy.
One third of remaining 50% with organ confined disease actually have micrometastatic disease at time of surgery.
Patients with Stage II and III BC have a high risk of micrometastatic disease.
Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR.
63) A declining rate of completion ALND for patients with micrometastatic disease was documented nationwide by analysis of 1998-2005 data collected in the National Cancer Data Base.
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.
5 [micro]g/L have distant micrometastatic disease and are thus unlikely to benefit from salvage RT.
The fact that the PAP was the strongest predictor of long-term biochemical failure in patients with otherwise higher risk features reported here suggests that it may be a more accurate indicator of micrometastatic disease compared with the Gleason score and the PSA level.
Available evidence suggests a lower rate of postoperative complications in patients who underwent completion lymph node dissection for micrometastatic disease detected by SLNB, compared to those who underwent therapeutic lymph node dissection for clinically palpable disease.
This means that adjuvant cancer therapy, designed to kill presumed micrometastatic disease, may be missing an important fraction of disseminated cancer cells, some of which may eventually wake up.
As the node is sectioned in 2-mm slices, it is likely that any discordant result is based on tissue less than 2 mm thick and therefore a positive result on molecular analysis with no histological evidence of metastases could be reasonably treated as micrometastatic disease.